A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma
A091903 is temporarily closed to new patient accrual to Pre-registration of Advanced Arm 3, effective June 16, 2025.